S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

BioMarin Pharmaceutical Stock Forecast, Price & News

+0.20 (+0.24%)
(As of 01/21/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.45 million shs
Average Volume
1.56 million shs
Market Capitalization
$15.54 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BioMarin Pharmaceutical logo

About BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.


10 Jim Cramer Stocks to Buy in Q1 2022
January 19, 2022 |  finance.yahoo.com
BioMarin Pharmaceutical Is Ready to Start a Fresh Advance
January 12, 2022 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.86 billion
Cash Flow
$1.23 per share
Book Value
$22.62 per share


Net Income
$859.10 million
Pretax Margin




Free Float
Market Cap
$15.54 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.75 out of 5 stars

Medical Sector

53rd out of 1,418 stocks

Pharmaceutical Preparations Industry

17th out of 683 stocks

Analyst Opinion: 4.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

Is BioMarin Pharmaceutical a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioMarin Pharmaceutical stock.
View analyst ratings for BioMarin Pharmaceutical
or view top-rated stocks.

How has BioMarin Pharmaceutical's stock been impacted by Coronavirus (COVID-19)?

BioMarin Pharmaceutical's stock was trading at $86.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BMRN stock has decreased by 2.6% and is now trading at $84.65.
View which stocks have been most impacted by COVID-19

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for BioMarin Pharmaceutical

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its quarterly earnings data on Tuesday, October, 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.05. The biotechnology company had revenue of $408.74 million for the quarter, compared to analyst estimates of $435.29 million. BioMarin Pharmaceutical had a net margin of 0.86% and a trailing twelve-month return on equity of 2.02%. The company's revenue was down 14.3% on a year-over-year basis. During the same quarter last year, the business posted $0.29 earnings per share.
View BioMarin Pharmaceutical's earnings history

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY 2021 earnings guidance on Wednesday, November, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.82 billion-$1.88 billion, compared to the consensus revenue estimate of $1.85 billion.

What price target have analysts set for BMRN?

14 Wall Street analysts have issued 1-year target prices for BioMarin Pharmaceutical's shares. Their forecasts range from $88.00 to $152.00. On average, they anticipate BioMarin Pharmaceutical's stock price to reach $112.57 in the next year. This suggests a possible upside of 33.0% from the stock's current price.
View analysts' price targets for BioMarin Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the following people:
  • Jean-Jacques Bienaimé, Chairman & Chief Executive Officer
  • Brian R. Mueller, Chief Financial Officer & Executive Vice President
  • Eduardo E. von Pervieux, Chief Information Officer
  • Henry J. Fuchs, President-Worldwide Research & Development
  • Adora Ndu, VP-World Wide Research & Development

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

161 employees have rated BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among BioMarin Pharmaceutical's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.29%), Frontier Capital Management Co. LLC (0.24%), Asymmetry Capital Management L.P. (0.10%), DNB Asset Management AS (0.09%), Royal London Asset Management Ltd. (0.03%) and Exchange Traded Concepts LLC (0.01%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, David E I Pyott, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends for BioMarin Pharmaceutical

Which major investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Moody National Bank Trust Division, Exchange Traded Concepts LLC, Royal London Asset Management Ltd., IBM Retirement Fund, IFM Investors Pty Ltd, Kestra Advisory Services LLC, and Inspirion Wealth Advisors LLC. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, George Eric Davis, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Richard A Meier, and V Bryan Lawlis.
View insider buying and selling activity for BioMarin Pharmaceutical
or view top insider-selling stocks.

Which major investors are buying BioMarin Pharmaceutical stock?

BMRN stock was bought by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., Scout Investments Inc., DNB Asset Management AS, First Hawaiian Bank, Stonnington Group LLC, New England Research & Management Inc., Cutler Group LP, and Wedbush Securities Inc..
View insider buying and selling activity for BioMarin Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $84.65.

How much money does BioMarin Pharmaceutical make?

BioMarin Pharmaceutical has a market capitalization of $15.54 billion and generates $1.86 billion in revenue each year. The biotechnology company earns $859.10 million in net income (profit) each year or $0.08 on an earnings per share basis.

How many employees does BioMarin Pharmaceutical have?

BioMarin Pharmaceutical employs 3,059 workers across the globe.

When was BioMarin Pharmaceutical founded?

BioMarin Pharmaceutical was founded in 1997.

What is BioMarin Pharmaceutical's official website?

The official website for BioMarin Pharmaceutical is www.bmrn.com.

Where are BioMarin Pharmaceutical's headquarters?

BioMarin Pharmaceutical is headquartered at 770 Lindaro Street, San Rafael CA, 94901.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at (415) 506-6700, via email at [email protected], or via fax at 415-382-7889.

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.